Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5881MR)

This product GTTS-WQ5881MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Hepatitis C research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5881MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10779MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ12972MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ6357MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ12466MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ14024MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3500
GTTS-WQ2662MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ699MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ6904MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW